These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23428919)

  • 1. Clinical status and outcome of Japanese heart failure patients with reduced or preserved ejection fraction treated with carvedilol.
    Mori Y; Nishikawa Y; Kobayashi F; Hiramatsu K
    Int Heart J; 2013; 54(1):15-22. PubMed ID: 23428919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
    Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
    Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of nebivolol and carvedilol on left ventricular diastolic function in older heart failure patients with preserved ejection fraction: study protocol for a randomized controlled trial.
    Park K; Park TH
    Trials; 2016 Nov; 17(1):530. PubMed ID: 27809882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
    Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
    J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.
    Hori M; Nagai R; Izumi T; Matsuzaki M
    Heart Vessels; 2014 Mar; 29(2):238-47. PubMed ID: 23559359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
    Massie BM; Nelson JJ; Lukas MA; Greenberg B; Fowler MB; Gilbert EM; Abraham WT; Lottes SR; Franciosa JA;
    Am J Cardiol; 2007 May; 99(9):1263-8. PubMed ID: 17478155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Dose β-Blocker Therapy Triggers Additional Reverse Remodeling in Patients With Idiopathic Non-Ischemic Cardiomyopathy.
    Nitta D; Kinugawa K; Imamura T; Kato NP; Komuro I
    Int Heart J; 2016 Dec; 57(6):717-724. PubMed ID: 27818482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure.
    Fujimura M; Akaike M; Iwase T; Yoshida S; Sumitomo Y; Yagi S; Ikeda Y; Hashizume S; Aihara K; Nishiuchi T; Yasumura Y; Matsumoto T
    Acta Cardiol; 2009 Oct; 64(5):589-95. PubMed ID: 20058503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
    Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
    Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers.
    Lindenfeld J; Robertson AD; Lowes BD; Bristow MR;
    J Am Coll Cardiol; 2001 Dec; 38(7):1950-6. PubMed ID: 11738299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discharge use of carvedilol is associated with higher survival in Japanese elderly patients with heart failure regardless of left ventricular ejection fraction.
    Yanagihara K; Kinugasa Y; Sugihara S; Hirai M; Yamada K; Ishida K; Kato M; Yamamoto K
    J Cardiovasc Pharmacol; 2013 Nov; 62(5):485-90. PubMed ID: 24072178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure.
    Palazzuoli A; Bruni F; Puccetti L; Pastorelli M; Angori P; Pasqui AL; Auteri A
    Eur J Heart Fail; 2002 Dec; 4(6):765-70. PubMed ID: 12453548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term outcome and tolerability of carvedilol therapy in Japanese patients with chronic heart failure].
    Kawashiro N; Matsuda N; Endo Y; Uchida Y; Kasanuki H
    J Cardiol; 2006 May; 47(5):229-37. PubMed ID: 16764329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure.
    Fragasso G; Spoladore R; Maranta F; Corti A; Lattuada G; Colombo B; Locatelli M; Salerno A; Calori G; Briceno L; Alfieri AB; Perseghin G; Margonato A
    J Cardiovasc Med (Hagerstown); 2013 Jan; 14(1):49-56. PubMed ID: 23018486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.
    van Veldhuisen DJ; Linssen GC; Jaarsma T; van Gilst WH; Hoes AW; Tijssen JG; Paulus WJ; Voors AA; Hillege HL
    J Am Coll Cardiol; 2013 Apr; 61(14):1498-506. PubMed ID: 23500300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure.
    Yoshizawa A; Yoshikawa T; Nakamura I; Satoh T; Moritani K; Suzuki M; Baba A; Iwanaga S; Mitamura H; Ogawa S
    J Card Fail; 2004 Aug; 10(4):310-5. PubMed ID: 15309697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
    Jourdain P; Funck F; Fulla Y; Hagege A; Bellorini M; Guillard N; Loiret J; Thebault B; Desnos M
    Eur J Heart Fail; 2002 Jun; 4(3):269-76. PubMed ID: 12034151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Beneficial neurohormonal profiles of beta-blockades in chronic left heart failure].
    Wang F; Xu ZM; Wang L; Bian WY; Jia X; Duan B; Li W; Li YS
    Zhonghua Nei Ke Za Zhi; 2005 Jul; 44(7):490-4. PubMed ID: 16080835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
    Li N; Li Y; Wang F; Jiang W; Huang J; Xu Z; Hua L; Hua C; Huang Y; Wu Y; Li F
    Clin Cardiol; 2007 Sep; 30(9):469-74. PubMed ID: 17803204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.